Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Vaccinex, Inc. is a clinical-stage biotechnology company focused on the discovery and development of differentiated monoclonal antibody therapies for the treatment of cancer and inflammatory and neurodegenerative diseases. The company operates within the biopharmaceutical and biotechnology industries, with a primary emphasis on immuno-oncology and central nervous system (CNS) disorders. Vaccinex’s core value proposition is its antibody discovery platform, which is designed to generate fully human monoclonal antibodies targeting novel biological pathways.
The company’s lead product candidate, pepinemab, is a monoclonal antibody targeting the semaphorin 4D (SEMA4D) pathway and represents the primary revenue-driving asset under development. Vaccinex serves pharmaceutical partners, clinical research institutions, and ultimately patients in specialized therapeutic areas with high unmet medical need. Founded in the late 1990s, the company evolved from a platform-focused antibody discovery enterprise into a clinical-stage developer with internally advanced drug candidates, culminating in its public listing on Nasdaq under the ticker VCNX.
Business Operations
Vaccinex generates value primarily through the research, development, and clinical advancement of proprietary antibody-based therapeutics. Its operations are organized around antibody discovery and development, with clinical programs targeting oncology indications and CNS diseases such as Alzheimer’s disease and Huntington’s disease. The company does not currently report commercial product revenue and relies on equity financing, grants, and strategic collaborations to fund operations.
The company’s proprietary technologies include a high-throughput antibody discovery engine and translational research capabilities supporting clinical development. Vaccinex conducts operations predominantly in the United States, with clinical trials and research collaborations extending internationally. Public disclosures reference research collaborations and clinical trial partnerships with academic and industry participants; however, details of current large-scale pharmaceutical partnerships are limited, and some previously announced collaborations appear to have concluded or evolved, with data inconclusive based on available public sources.
Strategic Position & Investments
Vaccinex’s strategic direction centers on advancing pepinemab through late-stage clinical evaluation while leveraging its discovery platform to identify additional antibody candidates. Growth initiatives have focused on expanding clinical indications for pepinemab across both oncology and neurodegenerative diseases, aiming to demonstrate differentiated efficacy and safety profiles compared to existing therapies.
The company has historically pursued selective collaborations and non-dilutive funding opportunities rather than large-scale acquisitions. Vaccinex does not report a broad portfolio of operating subsidiaries or significant equity investments in other companies. Its strategic positioning emphasizes emerging immunomodulatory pathways and CNS-focused immunotherapy, areas that remain scientifically active but commercially challenging, with outcomes dependent on ongoing and future clinical trial results.
Geographic Footprint
Vaccinex is headquartered in Rochester, New York, which serves as its primary center for executive management, research, and administrative operations. The company’s operational footprint is primarily within North America, with the majority of employees and facilities located in the United States.
International presence is mainly indirect, achieved through global clinical trials, contract research organizations, and academic collaborations in Europe and other regions. While Vaccinex does not maintain significant overseas offices, its clinical development programs and scientific partnerships give it exposure to multiple international markets and regulatory environments.
Leadership & Governance
Vaccinex was founded by Maurice R. Zauderer, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team combines experience in biotechnology research, clinical development, and public company management. The company’s governance structure reflects its status as a publicly traded clinical-stage biotechnology firm, with oversight by a board of directors and adherence to U.S. public company regulatory standards.
Key executives emphasize a strategy centered on scientific rigor, disciplined capital allocation, and targeted clinical development aimed at high-impact indications with unmet needs.
- Maurice R. Zauderer – President and Chief Executive Officer
- Andrew J. Allen – Chief Financial Officer
- Hanina Hibshoosh, Ph.D. – Chief Scientific Officer
- Kenneth S. Rock – Senior Vice President, Research and Development